

PRESENTED BY:



SPONSORED BY:



CONTINUING MEDICAL EDUCATION

SCT APP Curriculum - Transplant-Associated Thrombotic Microangiopathy: Clinical Features, Laboratory Evaluation, & Treatment - 3/4/2026 – 78472-71399

Date: March 4, 2026

Time: 8:00 AM-8:30 AM

UH Cleveland Medical Center

Lindsay Tomcsanyi, PharmD

University Hospitals Cleveland Medical Center

Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 1. Describe the pathophysiology, clinical presentation, and diagnostic considerations of TA-TMA, including differentiation from other post-transplant complications
- 2 2. Interpret key laboratory and diagnostic markers used in evaluation and monitoring, including appropriate test ordering and the clinical significance of results
- 3 3. Explain the current treatment algorithm at UH, including the role of eculizumab, and discuss emerging therapies with a focus on narsoplimab

Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Lauren Brister, MSN, APRN-CNP	Other Planning Committee Member	Nothing to disclose - 07/03/2025
Brenda Cooper, MD	Course Director	Nothing to disclose - 06/24/2025
Molly Gallogly, MD, PhD	Other Planning Committee Member	Consulting Fee-Incyte Consulting Fee-Techspert Speakers Bureau-Lilly Honoraria-MJH Life Sciences Consulting Fee-Citrus Health

PRESENTED BY:



SPONSORED BY:



		Group (Relationship has ended) Consulting Fee-The Dedham Group (Relationship has ended) - 06/09/2025
James J Ignatz-Hoover , MD, PhD	Other Planning Committee Member	Speakers Bureau-Sanofi-Aventis - 06/05/2025
Leland Metheny, MD	Other Planning Committee Member	Speakers Bureau-Incyte Speakers Bureau-Taiho Advisor-Bristol-Myers Squibb (Relationship has ended) Advisor-Gamida - 07/23/2025
Frank Oley, PharmD	Other Planning Committee Member	Nothing to disclose - 04/24/2025
Lindsay Tomcsanyi, PharmD	Faculty	Nothing to disclose - 02/02/2026
Benjamin Tomlinson, MD	Other Planning Committee Member	Advisor-Bristol-Myers Squibb Aventis (Relationship has ended) - 07/09/2025
Koen van Besien, MD, PhD	Other Planning Committee Member	Stocks or stock options, excluding diversified mutual funds- Hemogenyx Stocks or stock options, excluding diversified mutual funds- Avertix Advisor-autolus Advisor-ADC Therapeutics Advisor-intellia (Relationship has ended) Advisor-morphosys (Relationship has ended) Advisor-crispr (Relationship has ended) Advisor-incyte (Relationship has ended) Advisor-adbio - 07/31/2025